if so, at what average price
you are posting today that you own over 1.4 million shares but yesterday you said you sold out...
Reply to: AVXL is the next JAZZ and the train is leaving by stephata75 •17 hours ago
ama0123456789 • 16 hours ago
I dumped all my ELTP shares over the past week. Through it all in AVXL. Will hold for 1-2 years.
"The way you collect shares and make money doing it is buy the shares you unload to the short at a cheaper price."
i'm getting a headache trying to figure that out
have never understood how shorting actually happens, or why there is no penalty for longs loaning shares -- there is no lock-up period or anything, longs just loan shares, get paid interest, and can sell like anyone else any time they want
everywhere else, not "everything" else
but the point is, the German pricing negotiation has gone on long enough that the odds are that Linda is going to let it slide until she set pricing in the U.S.
the hospital exemption was an impressive achievement but Northwest was not likely to have gotten much revenue from it anyhow -- though it is a mystery as to why non-German, self-paying patients are not flocking to Germany for treatment
biogen reported disappointing earnings which threw a blanket of gloom over the whole sector, but the revenue miss was due to German pricing -- and that is of particular importance to Northwest which may be why most of the sector has been recovering but NWBO is still dealing with a considerable drop
not a whole lot of retail investors are probably making that connection but institutions and shorts are
have been suspecting that Linda cannot get an acceptable price from Germany and has decided to wait until phase III results let her negotiate back home instead of letting Germany create a low bar for negotiations everything else
are you back to fully loaned out, or are shorts still finding cheaper shares
don't like that folks on this board (quite a few) are loaning to them but you provide something of a gauge for how confident the shorts are when you tell us that you are fully loaned or not, and what percentage they are paying
this was a report on very preliminary work done over a year ago that involved 16 dogs, and then one patient and one tumor
do you have any update
"Worse yet, the revenue miss came from Biogen's main growth driver, multiple sclerosis drug Tecfidera. It says a lot when a 26% year-over-year increase is considered a miss; but investors were hoping that international growth in Tecfidera could take over for stalling growth in the U.S.
Part of the subpar growth in Tecfidera has to do with a lower price for the drug in Germany -- international sales fell 8% quarter over quarter despite a 14% increase in volume."
Novel bought $2 million worth of Elite stock which gave them 5% ownership at that time
have no idea when Novel sold that, or if they have
what caused elite's ownership interest to drop was that elite could not put up the remaining $20 million or provide any further matching funds due to its financial condition -- unfortunately this allowed Novel to begin unilaterally diluting elite's ownership
this may also be the reason that Gavis was created as an 'affiliate' rather than a subsidiary which meant elite's ownership in Novel did not extend to Gavis where, essentially, all the revenues and profits would reside -- but all this was done before Hakim showed up, or even Jerry
in any case, there has been bad blood between Novel and Elite for years as evidenced by Elite going to Epic for financing instead of Novel, and Novel creating Gavis instead of utilizing Elite's manufacturing facility
but, again, all of this was before Jerry and Hakim, and was caused by Elite not being unable to continue funding Novel -- blame the former management
btw, considering Hakim had started an action against Novel in April last year he sure did sound gracious when discussing the $5 million on the cc
according to this filing from eight years ago it was 49 percent, but i think it started at 50/50...
"In December 2006, Elite entered into a joint venture with VGS Pharma, LLC and created Novel Laboratories, Inc., a privately-held company specializing in pharmaceutical research, development, manufacturing, licensing, acquisition and marketing of specialty generic pharmaceuticals. Novel’s business strategy is to focus on its core strength in identifying and timely executing niche business opportunities in the generic pharmaceutical area. Elite currently holds 49% and VGS holds 51% of Novel’s capital stock. Elite initially contributed $2,000,000 to Novel in December 2006 and on May 15 and June 15, 2007, Elite contributed $2,000,000 and $3,000,000, respectively. The remaining contributions to be made by Elite in order to maintain its full equity interest in Novel equal $20,000,000.
As of June 15, 2007, Novel has 30 employees, has identified 22 generic product opportunities and is actively developing 11 generic products. It is Novel’s general policy not to disclose products in its development pipeline or the status of such products until a product reaches a stage that we determine, for competitive reasons, in our discretion, to be appropriate for disclosure."
afrezza was not supposed to need magazine ads
it was supposed to be one of the most anticipated drugs of all time
folks were supposed to be chomping at the bit to ditch their needles
diabetics were supposed to be lined up outside doctors' offices
because everybody knew what afrezza was and when it was coming out
so awareness cannot be the issue, cannot be blamed for the lack of sales
doctors seeing diabetics are certainly keeping up on advances AND have by now been contacted by a sanofi rep if the doctor has ever prescribed any sanofi drug
hence, the problem is acceptance not awareness
and that is not good because it means doctors and or patients are rejecting afrezza
maybe when those long term safety studies are done the level of acceptance will go up, but until then it looks like afrezza is going to muddle along and maybe not even pay the bills
if afrezza does not meet sales targets, sanofi takes over the product including the patent and the inventory -- all according to the terms of the agreement
sanofi's plan is to have afrezza in the long term but, for now, their focus is on selling their own stuff where they get to keep all the profits
how are they able to keep their licenses if they are that much out of touch with current medical advances
final results have to released within 72 hours of Hakim receiving them
i really think that short volume is just trades that went at the bid instead of the ask
there is no way there could be so much shorting, or any shorting, of ELTP -- what broker do you know that would accept a short order on a .23 stock
oops, typo -- Elite's initial ownership interest was 49% not 40%
frankly, it seems it was actually 50% which would be a full partnership, but the SEC filing from back then says 49%
because Novel set up Gavis as an affiliate, Elite had no ownership interest
and because Novel created Gavis to handle manufacturing and distribution meant all the revenues and profits were parked over there, i.e., Novel was pure R&D
which may be why Hakim started an action against Novel in April of 2014 which was then dropped when he accepted the $5 million settlement
when brought up on the cc at the time, Hakim did not seem 'happy' with the settlement but basically said it was good to get that distraction behind us and move on
Elite definitely got short changed, but the problem was, after helping to fund Novel when the partnership was formed in 2007, Elite stopped making matching contributions and its ownership interest dropped from 40% to 10% such that Elite had no say it what was being done -- at least in Nevada...things might have been different if they had stayed incorporated in New Jersey